Phase 1 N=146 Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product
Healthy Volunteer
Primary: Maximum Observed Drug Concentration (Cmax) of Denosumab — 12.7; 11.8 μg/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=24 Pharmacokinetic Study Of AGILE AG200-15 After Weekly Application Under Various Conditions in Healthy Female Volunteers
Healthy
Primary: Area Under the Concentration Versus Time Curve (AUC) (0-168) Profile of Levonorgestrel (LNG) — 157; 118; 153; 137 ng*hr/mL
Phase 1 N=12 RDEA3170 and Allopurinol Combination Study in Gout Subjects
Gout
Primary: Maximum Observed Plasma Concentration (Cmax) — 1.13; 1.51; 12.8; 8.68 μg/mL
Phase 1 N=36 AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol
Healthy
Primary: Comparative Evaluation of Ethinyl Estradiol (EE) Cmax Between AG200-15 and Ortho-Cyclen® in Week 1 — 135; 45.5 pg/ml — p=<0.0001
Phase 1 N=36 Phase 1 Safety and Immunogenicity of Meningococcal Vaccine
Meningococcal Infection, Group B
Primary: Bactericidal Absolute Values After Group B Meningococcal 8570 HOPS-G NOMV Vaccine Injections — 2.1; 3.0; 3.0; 2.4 titers
Phase 1 N=18 Effect of Slow Release Hydrocortisone on Fed & Fasting Volunteers; Immediate Release on Fasting Only
Healthy
Primary: Chronocort Cmax — 549.49; 708.46; 856.36 nmol/L
Phase 1 N=30 Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Phase 1 Sickle Cell
Primary: Number of Participants With Potentially Clinically Important (PCI) Change From Baseline in Vital Signs — 0; 0; 0; 2 participants
Phase 1 N=23 Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies
Cancer · Advanced Solid Malignancies
Primary: Number of Participants With Adverse Events — 4; 7; 10; 1 Participants
Phase 1 N=33 A Study of Baricitinib (LY3009104) in Healthy Chinese Participants
Healthy
Primary: Number of Participants With One or More Clinically Significant Event(s) — 4; 0; 2; 4 Participants
Phase 1 N=25 Study of the Safety of QRH-882260 Heptapeptide
Healthy Adults
Primary: Number of Subjects With Abnormal Lab Values — 1 Participants
Phase 1 N=18 A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer
Stomach Neoplasms
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 1; 2; 2 Participants
Phase 1 N=40 Thorough QT Study of Intravenous Amisulpride
Healthy
Primary: Maximal Mean ΔΔQTcF — 5.0; 23.4; 0.8; 12.3 milliseconds
Phase 1 N=24 Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy Subjects
Hepatic Impairment
Primary: Assessment of Maximum Observed Plasma Drug Concentration (Cmax) for Telotristat Ethyl and Comparison Between Each HI Group and Healthy Control Group — 4.06; 6.88; 9.99…
Phase 1 N=56 Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects
Healthy
Primary: AUC0-tz (Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) — 2550; 2510 nmol*h/L…
Phase 1 N=12 A Food Effect Study of TAK-385 Final Formulation
Japanese Premenopausal Healthy Adult Women
Primary: Cmax: Maximum Observed Plasma Concentration for TAK-385 — 23.44; 29.05; 10.94 nanogram per milliliter (ng/mL) — p=0.659